Pro-Pharma/Sanghyon agency accord

Pro-Pharmaceuticals, a US biopharmaceutical firm developing proprietary polysaccharide-based therapeutic compounds for the treatment of cancer and fibrosis, has entered into an agency agreement with Sanghyon Chemical to represent the group with major pharmaceutical companies in South Korea. Sanghyon will provide for the registration of Davant, a proprietary carbohydrate polymer that is administered with chemotherapies and biologics, with the Korean Food and Drug Administration and marketing and sales support for the licensing and distribution of the product to treat cancer with chemotherapy drugs.

"The collaboration with Sanghyon Chemical is another step in the realization of commercializing Davant on a regional basis," said Theodore Zucconi, president of Pro-Pharmaceuticals. "We continue to pursue partnerships with regional distributors who understand how to do business in their regions, as well as with several large international pharmaceutical companies. Sanghyon is an experienced partner that will enable us to penetrate a major market such as Korea," he added.